Evidence
J Pharm Anal. 2024 May;14(5):100913. doi: 10.1016/j.jpha.2023.12.003. Epub 2023 Dec 13.
ABSTRACT
Obesity and related metabolic syndromes have been recognized as important disease risks, in which the role of adipokines cannot be ignored. Adiponectin (ADP) is one of the key adipokines with various beneficial effects, including improving glucose and lipid metabolism, enhancing insulin sensitivity, reducing oxidative stress and inflammation, promoting ceramides degradation, and stimulating adipose tissue vascularity. Based on those, it can serve as a positive regulator in many metabolic syndromes, such as type 2 diabetes (T2D), cardiovascular diseases, non-alcoholic fatty liver disease (NAFLD), sarcopenia, neurodegenerative diseases, and certain cancers. Therefore, a promising therapeutic approach for treating various metabolic diseases may involve elevating ADP levels or activating ADP receptors. The modulation of ADP genes, multimerization, and secretion covers the main processes of ADP generation, providing a comprehensive orientation for the development of more appropriate therapeutic strategies. In order to have a deeper understanding of ADP, this paper will provide an all-encompassing review of ADP.
PMID:38799237 | PMC:PMC11127227 | DOI:10.1016/j.jpha.2023.12.003
Estimated reading time: 3 minute(s)
Latest: Psychiatryai.com #RAISR4D Evidence
Cool Evidence: Engaging Young People and Students in Real-World Evidence
Real-Time Evidence Search [Psychiatry]
AI Research
New advances of adiponectin in regulating obesity and related metabolic syndromes
🌐 90 Days
AI Virtual Reality Related Evidence Matrix
- Molecular and pathophysiological relationship between obesity and chronic inflammation in the manifestation of metabolic dysfunctions and their inflammation‑mediating treatment options (Review)
- Adipose Tissue Insulin Resistance in South Asian and Nordic Women after Gestational Diabetes Mellitus
- Role of FXR in the development of NAFLD and intervention strategies of small molecules
- White Adipose Tissue in Metabolic Associated Fatty Liver Disease
- Unleashing the potential of adipose organoids: A revolutionary approach to combat obesity-related metabolic diseases
- Roles and Mechanisms of Choline Metabolism in Nonalcoholic Fatty Liver Disease and Cancers
- Role of the angiopoietin-like protein family in the progression of NAFLD
- Role of lactate and lactate metabolism in liver diseases (Review)
- Kaempferol efficacy in metabolic diseases: Molecular mechanisms of action in diabetes mellitus, obesity, non-alcoholic fatty liver disease, steatohepatitis, and atherosclerosis
- Intestinal Barrier Dysfunction and Gut Microbiota in Non-Alcoholic Fatty Liver Disease: Assessment, Mechanisms, and Therapeutic Considerations
- Adiposity, immunity, and inflammation: interrelationships in health and disease: A report from 24th annual Harvard nutrition obesity symposium, June 2023
- From NAFLD to NASH: Understanding the spectrum of non-alcoholic liver diseases and their consequences
- Obesity and Depression: Common Link and Possible Targets
- MAFLD as part of systemic metabolic dysregulation
- MAFLD as part of systemic metabolic dysregulation
- Regulatory pathways and therapeutic potential of PDE4 in liver pathophysiology
- Pro- and anti-inflammatory cytokines are the game-changers in childhood obesity-associated metabolic disorders (diabetes and non-alcoholic fatty liver diseases)
- Inflammatory liver diseases and susceptibility to sepsis
- Evaluation of the Diagnostic Utility of Selected Serum Adipokines and Cytokines in Subjects with MASLD-A Pilot Study
- Epidemiology, screening, and Co-management of type 2 diabetes mellitus and Metabolic-dysfunction associated steatotic liver disease
- Exploring the role of genetic variations in NAFLD: implications for disease pathogenesis and precision medicine approaches
- Muscle strength and non-alcoholic fatty liver disease/metabolic-associated fatty liver disease
- Akkermansia muciniphila: a potential candidate for ameliorating metabolic diseases
- Tangshen formula targets the gut microbiota to treat non-alcoholic fatty liver disease in HFD mice: A 16S rRNA and non-targeted metabolomics analyses
- Roflumilast ameliorates GAN diet-induced non-alcoholic fatty liver disease by reducing hepatic steatosis and fibrosis in ob/ob mice
- Tartaric acid ameliorates experimental non-alcoholic fatty liver disease by activating the AMP-activated protein kinase signaling pathway
- Tartaric acid ameliorates experimental non-alcoholic fatty liver disease by activating the AMP-activated protein kinase signaling pathway
- Population-enriched innate immune variants may identify candidate gene targets at the intersection of cancer and cardio-metabolic disease
- Population-enriched innate immune variants may identify candidate gene targets at the intersection of cancer and cardio-metabolic disease
- Role of Angiotensin II in Non-Alcoholic Steatosis Development
- Advances in management of metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutics
- A Review: Cytochrome P450 in Alcoholic and Non-Alcoholic Fatty Liver Disease
- Semaglutide alters gut microbiota and improves NAFLD in db/db mice
- EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
- THE GLOBAL EPIDEMIOLOGY OF NON-ALCOHOLIC FATTY LIVER DISEASE AND NON-ALCOHOLIC STEATOHEPATITIS AMONG PATIENTS WITH TYPE 2 DIABETES
- Effects of the Pituitary-targeted Gland Axes on Hepatic Lipid Homeostasis in Endocrine-associated Fatty Liver Disease-A Concept Worth Revisiting
- Interplay between metabolic dysfunction-associated fatty liver disease and renal function: An intriguing pediatric perspective
- Integrated spatial metabolomics and transcriptomics decipher the hepatoprotection mechanisms of wedelolactone and demethylwedelolactone on non-alcoholic fatty liver disease
- Predictors for liver fibrosis in non-alcoholic patients with psoriatic diseases: A multicenter cross sectional-study
- Predictors for liver fibrosis in non-alcoholic patients with psoriatic diseases: A multicenter cross sectional-study
- Effects of Ganjianglingzhu Decoction on Lean Non-Alcoholic Fatty Liver Disease in Mice Based on Untargeted Metabolomics
- The Transition in Terminology: From Non-alcoholic Fatty Liver Disease (NAFLD) to Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) to Metabolic-associated Steatotic Liver Disease (MASLD)
- Hypercaloric low-carbohydrate high-fat diet protects against the development of nonalcoholic fatty liver disease in obese mice in contrast to isocaloric Western diet
- Management of Cardiovascular Risk in the Non-alcoholic Fatty Liver Disease Setting
- Metabolic Dysfunction-associated Fatty Liver Disease: An Urgent Call for Global Action
- The deleterious effects and potential therapeutic strategy of fluorene-9-bisphenol on circadian activity and liver diseases in zebrafish and mice
- Fructose induces hepatic steatosis in adolescent mice linked to the disorders of lipid metabolism, bile acid metabolism, and autophagy
- The advent of RNA-based therapeutics for metabolic syndrome and associated conditions: a comprehensive review of the literature
- Epigenetic/circadian clocks and PCOS
- Targeting metabolic-associated fatty liver disease in diabetic kidney disease: A call to action
- Single-Cell Data Analysis Reveals Critical Hepatic Cells Subpopulations in the Progression of Non-alcoholic Fatty Liver Disease to Non-Alcoholic Steatohepatitis
- Glycyrrhizin and the Related Preparations: An Inspiring Resource for the Treatment of Liver Diseases
- Hedan tablet ameliorated non-alcoholic steatohepatitis by moderating NF-kappaB and lipid metabolism-related pathways via regulating hepatic metabolites
- Lipidomic Analysis of Liver and Adipose Tissue in a High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease Mice Model Reveals Alterations in Lipid Metabolism by Weight Loss and Aerobic Exercise
- Managing the Patient with Psoriasis and Metabolic Comorbidities
- Incretin-based investigational therapies for the treatment of MASLD/MASH
- Spleen volume is independently associated with non-alcoholic fatty liver disease, liver volume and liver fibrosis
- The association of Neuromedin U levels and non-alcoholic fatty liver disease: A comparative analysis
- Multiscale 3D genome organization underlies duck fatty liver with no adipose inflammation or serious injury
- Coexistence of metabolic-associated fatty liver disease and autoimmune or toxic liver disease
- Breaking the barriers: the role of gut homeostasis in Metabolic-Associated Steatotic Liver Disease (MASLD)
- Influence of glucagon-like peptide-1 receptor agonists on fat accumulation in patients with diabetes mellitus and non-alcoholic fatty liver disease or obesity: A systematic review and meta-analysis of randomized control trials
- Diagnostic performance of the GGT/HDL-C ratio for NAFLD in adults with obesity undergoing bariatric surgery
- Extract of Silphium perfoliatum L. improve lipid accumulation in NAFLD mice by regulating AMPK/FXR signaling pathway
Evidence Blueprint
New advances of adiponectin in regulating obesity and related metabolic syndromes
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
New advances of adiponectin in regulating obesity and related metabolic syndromes
🌐 365 Days
AI Virtual Reality Related Evidence Matrix
- Transcription factor EB: A potential integrated network regulator in metabolic-associated cardiac injury
- Molecular and pathophysiological relationship between obesity and chronic inflammation in the manifestation of metabolic dysfunctions and their inflammation‑mediating treatment options (Review)
- Phytochemicals for the treatment of metabolic diseases: Evidence from clinical studies
- Why do some glucose-lowering agents improve non-alcoholic fatty liver disease whereas others do not? A narrative review in search of a unifying hypothesis
- Pregnane X receptor activation remodels glucose metabolism to promote NAFLD development in obese mice
- Adipose Tissue Insulin Resistance in South Asian and Nordic Women after Gestational Diabetes Mellitus
- Reduced Lipopolysaccharide-Binding Protein (LBP) Levels Are Associated with Non-Alcoholic Fatty Liver Disease (NAFLD) and Adipose Inflammation in Human Obesity
- Synergistic effect rescue animal model from NASH caused by diet-inflammation inducer
- Cardiovascular significance of adipose-derived adiponectin and liver-derived xanthine oxidoreductase in metabolic syndrome
- SCD1 is the critical signaling hub to mediate metabolic diseases: Mechanism and the development of its inhibitors
- Adipose-derived extracellular vesicles - a novel cross-talk mechanism in insulin resistance, non-alcoholic fatty liver disease, and polycystic ovary syndrome
- Role of FXR in the development of NAFLD and intervention strategies of small molecules
- White Adipose Tissue in Metabolic Associated Fatty Liver Disease
- A Novel Drosophila Model to Investigate Adipose Tissue Macrophage Infiltration (ATM) and Obesity highlights the Therapeutic Potential of Attenuating Eiger/TNFα Signaling to Ameliorate Insulin Resistance and ATM
- Myeloid-derived growth factor and its effects on cardiovascular and metabolic diseases
- Therapeutic Activity of Green Tea Epigallocatechin-3-Gallate on Metabolic Diseases and Non-Alcoholic Fatty Liver Diseases: The Current Updates
- Peripheral and central macrophages in obesity
- Celastrol attenuates HFD-induced obesity and improves metabolic function independent of adiponectin signaling
- Lipophagy: A potential therapeutic target for nonalcoholic and alcoholic fatty liver disease
- Unleashing the potential of adipose organoids: A revolutionary approach to combat obesity-related metabolic diseases
- SGLT-2 Inhibitors for Non-Alcoholic Fatty Liver Disease: A Review
- Roles and Mechanisms of Choline Metabolism in Nonalcoholic Fatty Liver Disease and Cancers
- Role of the angiopoietin-like protein family in the progression of NAFLD
- Role of lactate and lactate metabolism in liver diseases (Review)
- Kaempferol efficacy in metabolic diseases: Molecular mechanisms of action in diabetes mellitus, obesity, non-alcoholic fatty liver disease, steatohepatitis, and atherosclerosis
- Glucokinase regulatory protein: a balancing act between glucose and lipid metabolism in NAFLD
- Non-alcoholic fatty liver disease, metabolic syndrome, and type 2 diabetes mellitus: where do we stand today?
- Research progress of celastrol on the prevention and treatment of metabolic associated fatty liver disease
- Effect of the nomenclature of non-alcoholic fatty liver disease on diagnosis and treatment of fatty liver disease concomitant with other liver diseases
- Intestinal Barrier Dysfunction and Gut Microbiota in Non-Alcoholic Fatty Liver Disease: Assessment, Mechanisms, and Therapeutic Considerations
- Mitochondrial metabolic dysfunction and non-alcoholic fatty liver disease: new insights from pathogenic mechanisms to clinically targeted therapy
- Adiposity, immunity, and inflammation: interrelationships in health and disease: A report from 24th annual Harvard nutrition obesity symposium, June 2023
- Adipose tissue fibrosis: the unwanted houseguest invited by obesity
- Sex- and age-specific associations between abdominal fat and non-alcoholic fatty liver disease: a prospective cohort study
- From NAFLD to NASH: Understanding the spectrum of non-alcoholic liver diseases and their consequences
- Cell-type specific role of autophagy in the liver and its implications in non-alcoholic fatty liver disease
- Insulin resistance and adipose tissue interactions as the cornerstone of metabolic (dysfunction)-associated fatty liver disease pathogenesis
- Obesity and Depression: Common Link and Possible Targets
- The role of Sirtuin 2 in liver - An extensive and complex biological process
- Various types of fasting diet and possible benefits in nonalcoholic fatty liver: Mechanism of actions and literature update
- Curative role of natural PPARγ agonist in non-alcoholic fatty liver disease (NAFLD)
- The role of lipid dysregulation in gestational diabetes mellitus: Early prediction and postpartum prognosis
- The Role of Phosphatidylethanolamine N-Methyltransferase (PEMT) and Its Waist-Hip-Ratio-Associated Locus rs4646404 in Obesity-Related Metabolic Traits and Liver Disease
- MASLD: a systemic metabolic disorder with cardiovascular and malignant complications
- Pharmacotherapies of NAFLD: updated opportunities based on metabolic intervention
- Plants of the Rubiaceae Family with Effect on Metabolic Syndrome: Constituents, Pharmacology, and Molecular Targets
- Metabolic complications of obesity in children and adolescents
- Mitochondrial Quality Control: Its Role in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
- Berberine prevents NAFLD and HCC by modulating metabolic disorders
- Biological Role and Related Natural Products of SIRT1 in Nonalcoholic Fatty Liver
- Physical exercise plays a role in rebalancing the bile acids of enterohepatic axis in non-alcoholic fatty liver disease
- MAFLD as part of systemic metabolic dysregulation
- MAFLD as part of systemic metabolic dysregulation
- Ginsenoside Rc: A potential intervention agent for metabolic syndrome
- Regulatory pathways and therapeutic potential of PDE4 in liver pathophysiology
- Anthocyanin: A Potential Phytochemical Candidate for the Amelioration of Non-Alcoholic Fatty Liver Disease
- Pro- and anti-inflammatory cytokines are the game-changers in childhood obesity-associated metabolic disorders (diabetes and non-alcoholic fatty liver diseases)
- Ophiopogonin D ameliorates non‑alcoholic fatty liver disease in high‑fat diet‑induced obese mice by improving lipid metabolism, oxidative stress and inflammatory response
- Lipotoxicity: The missing link between diabetes and periodontitis?
- Prebiotics, Probiotics, and Synbiotics-A Research Hotspot for Pediatric Obesity
- Inflammatory liver diseases and susceptibility to sepsis
- Metabolic Dysfunction-Associated Steatotic Liver Disease: A State-of-the-Art Review
- Integrated traditional Chinese and Western medicine in the prevention and treatment of non-alcoholic fatty liver disease: future directions and strategies
- Transgenic mice lacking FGF15/19-SHP phosphorylation display altered bile acids and gut bacteria, promoting nonalcoholic fatty liver disease